206 related articles for article (PubMed ID: 37963387)
1. Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19).
Toure BB; Panakam A; Johns SL; Butler SK; Tuomala RE; Diouf K
Obstet Gynecol; 2024 Feb; 143(2):273-276. PubMed ID: 37963387
[TBL] [Abstract][Full Text] [Related]
2. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM
Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
[TBL] [Abstract][Full Text] [Related]
4. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
[TBL] [Abstract][Full Text] [Related]
5. Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.
Colaneri M; Scaglione G; Fassio F; Galli L; Lai A; Bergna A; Gabrieli A; Tarkowski M; Ventura CD; Colombo V; Cordier L; Bernasconi D; Corbellino M; Dedivitiis G; Borghetti S; Visigalli D; Sollima S; Casalini G; Rizzardini G; Gori A; Antinori S; Riva A; Schiavini M
Virol J; 2024 Mar; 21(1):68. PubMed ID: 38509536
[TBL] [Abstract][Full Text] [Related]
6. Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.
Aiello TF; Peyrony O; Chumbita M; Monzó P; Lopera C; Puerta-Alcalde P; Magnano L; Fernández-Avilés F; Cuesta G; Tuset M; Mensa J; Esteve J; Marcos MA; Soriano A; Garcia-Vidal C
Influenza Other Respir Viruses; 2024; 18(3):e13264. PubMed ID: 38468434
[TBL] [Abstract][Full Text] [Related]
7. Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019.
Chan GCK; Lui GCY; Wong CNS; Yip SST; Li TCM; Cheung CSK; Sze RKH; Szeto CC; Chow KM
Clin Infect Dis; 2023 Nov; 77(10):1406-1412. PubMed ID: 37531093
[TBL] [Abstract][Full Text] [Related]
8. Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study.
Han X; Li C; Yuan X; Cui J; Han Z; Meng J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Chen W; Xiong J; Zhao D; Zhang X; Han X; Cheng H; Yu Z; Shi Y; Xie W; Xie L
Ann Med; 2024 Dec; 56(1):2313062. PubMed ID: 38354691
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina.
Henderson HI; Wohl DA; Fischer WA; Bartelt LA; van Duin D; Agil DM; Browne LE; Li KP; Moy A; Eron JJ; Napravnik S
J Antimicrob Chemother; 2024 Apr; 79(4):859-867. PubMed ID: 38380946
[TBL] [Abstract][Full Text] [Related]
10. Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.
Jang YR; Oh Y; Kim JY
J Korean Med Sci; 2024 Feb; 39(6):e52. PubMed ID: 38374626
[TBL] [Abstract][Full Text] [Related]
11. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
[TBL] [Abstract][Full Text] [Related]
12. Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19).
Loza A; Farias R; Gavin N; Wagner R; Hammer E; Shields A
Obstet Gynecol; 2022 Sep; 140(3):447-449. PubMed ID: 36356238
[TBL] [Abstract][Full Text] [Related]
13. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir.
Gerhart J; Cox DS; Singh RSP; Chan PLS; Rao R; Allen R; Shi H; Masters JC; Damle B
Clin Pharmacokinet; 2024 Jan; 63(1):27-42. PubMed ID: 38177893
[TBL] [Abstract][Full Text] [Related]
14. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
Transpl Int; 2024; 37():12360. PubMed ID: 38596505
[TBL] [Abstract][Full Text] [Related]
15. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.
Singh RSP; Toussi SS; Hackman F; Chan PL; Rao R; Allen R; Van Eyck L; Pawlak S; Kadar EP; Clark F; Shi H; Anderson AS; Binks M; Menon S; Nucci G; Bergman A
Clin Pharmacol Ther; 2022 Jul; 112(1):101-111. PubMed ID: 35388471
[TBL] [Abstract][Full Text] [Related]
16. Predictors of nirmatrelvir-ritonavir receipt among COVID-19 patients in a large US health system.
Malden DE; McLaughlin JM; Hong V; Lewnard J; Ackerson BK; Puzniak L; Kim JS; Takhar H; Frankland TB; Slezak JM; Tartof SY
Sci Rep; 2024 Mar; 14(1):7485. PubMed ID: 38553527
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of physicians prescribing of COVID-19 guideline-directed outpatient treatments in a primary care walk-in clinic.
Denning K; Sheppard J; Carico R
J Am Pharm Assoc (2003); 2024; 64(2):530-534. PubMed ID: 38151202
[TBL] [Abstract][Full Text] [Related]
18. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.
Eng H; Dantonio AL; Kadar EP; Obach RS; Di L; Lin J; Patel NC; Boras B; Walker GS; Novak JJ; Kimoto E; Singh RSP; Kalgutkar AS
Drug Metab Dispos; 2022 May; 50(5):576-590. PubMed ID: 35153195
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Clinical Outcomes of Pregnant Patients Treated With Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection.
Garneau WM; Jones-Beatty K; Ufua MO; Mostafa HH; Klein SL; Burd I; Gebo KA
JAMA Netw Open; 2022 Nov; 5(11):e2244141. PubMed ID: 36445705
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY
Lancet Infect Dis; 2023 Jul; 23(7):806-815. PubMed ID: 36933565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
